IRF2 and colorectal carcinoma: In KRAS-mutant colorectal cancer (CRC), KRAS∗-mediated repression of interferon regulatory factor 2 (IRF2) that directly represses CXCL3 expression results in high expression of CXCL3, which binds to CXCR2 on MDSCs and promotes their migration to the TME.